Johnson & Johnson (NYSE:JNJ) Stock Holdings Lifted by Inscription Capital LLC

Inscription Capital LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 307.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,005 shares of the company’s stock after buying an additional 9,813 shares during the period. Johnson & Johnson makes up about 0.9% of Inscription Capital LLC’s investment portfolio, making the stock its 26th largest holding. Inscription Capital LLC’s holdings in Johnson & Johnson were worth $1,683,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Zions Bancorporation N.A. raised its position in Johnson & Johnson by 0.4% in the second quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock worth $2,810,000 after purchasing an additional 73 shares in the last quarter. Portland Global Advisors LLC grew its stake in Johnson & Johnson by 0.9% during the third quarter. Portland Global Advisors LLC now owns 8,744 shares of the company’s stock worth $1,131,000 after buying an additional 78 shares during the last quarter. Vishria Bird Financial Group LLC grew its stake in Johnson & Johnson by 3.0% during the second quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock worth $381,000 after buying an additional 80 shares during the last quarter. Alta Capital Management LLC grew its stake in Johnson & Johnson by 3.9% during the third quarter. Alta Capital Management LLC now owns 2,184 shares of the company’s stock worth $282,000 after buying an additional 82 shares during the last quarter. Finally, G&S Capital LLC grew its stake in shares of Johnson & Johnson by 1.8% during the third quarter. G&S Capital LLC now owns 4,668 shares of the company’s stock valued at $604,000 after purchasing an additional 84 shares during the last quarter. 72.25% of the stock is currently owned by institutional investors.

JNJ opened at $133.00 on Friday. The firm’s fifty day moving average is $130.83 and its two-hundred day moving average is $134.05. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. The firm has a market cap of $343.25 billion, a PE ratio of 16.26, a price-to-earnings-growth ratio of 2.20 and a beta of 0.69. Johnson & Johnson has a twelve month low of $121.00 and a twelve month high of $148.99.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.12. The company had revenue of $20.73 billion for the quarter, compared to analyst estimates of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period last year, the business posted $2.05 earnings per share. Equities analysts forecast that Johnson & Johnson will post 8.65 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a dividend of $0.95 per share. The ex-dividend date is Monday, November 25th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.86%. Johnson & Johnson’s payout ratio is 46.45%.

Several equities analysts recently weighed in on JNJ shares. Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a report on Wednesday, October 16th. Bank of America restated a “hold” rating and issued a $150.00 price objective on shares of Johnson & Johnson in a report on Tuesday, July 16th. Wells Fargo & Co cut their target price on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a report on Wednesday, October 16th. Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Finally, Raymond James cut their target price on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Johnson & Johnson currently has an average rating of “Buy” and an average target price of $151.64.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: What are some reasons analysts would give stocks a buy rating?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit